1-855-378-42281-855-378-4228
One of the outpatient treatment alternatives for people in Hazard who are struggling with opioid dependence and addiction is called opioid maintenance therapy. Licensed clinics and doctors are authorized to dispense certain meds to opioid addicted individuals, many of which are opioids also and are addictive. In low amounts however, the user doesn't feel high but also does not have acute cravings and is not in opioid withdrawal. Methadone is the first med tried for this reason, but there are a few more choices currently to choose from.
Methadone is an opiate and can be taken at an outpatient medical center certified to administer the med, that is taken daily as a pill or liquid. The cost of the drug is about $150 a month. Buprenorphine is also an opioid based med, and is in pill form often taken one day on, one day off. But different from Methadone which is only be dispensed in highly structured clinics, Buprenorphine can be and is prescribed and dispensed in doctor's offices. The monthly cost of buprenorphine is about just under $300 per month for the generic of the medication. There is also a type of buprenorphine that contains the ingredient naloxone, that is a drug which blocks the effects of opiates. A person consuming this formulation, AKA Suboxone, would find it more difficult to feel high from opioids if they relapsed while taking the drug. It is also taken every day, and costs around $450 a month. Naltrexone is another drug taken in opioid maintenance therapy, but unlike the other drugs mentioned it is an opiate blocker and isn't an opioid. A person has the choice to take this drug as a monthly injection, and that is called Vivitrol. As an opioid blocker, it prevents someone from experience high feelings from opioids, and in turn lowers the risk associated with relapse. This daily shot costs in the range of $1000 to $1200 /month.
There are 1 Alcohol and Drug Treatment Centers offering this service in Hazard, KY
For All Alcohol and Drug Treatment Programs In Hazard, Click Here.
